Scarica l'app Stockscreener
43.82
5.13%
2.14
Dopo l'orario di chiusura:
43.82
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$41.68
Aprire:
$41.7
Volume 24 ore:
1.34M
Relative Volume:
1.14
Capitalizzazione di mercato:
$3.49B
Reddito:
-
Utile/perdita netta:
$-237.22M
Rapporto P/E:
-11.59
EPS:
-3.78
Flusso di cassa netto:
$-212.64M
1 W Prestazione:
-1.59%
1M Prestazione:
-12.27%
6M Prestazione:
+71.04%
1 anno Prestazione:
+49.51%
Intervallo 1D:
$41.61
$43.92
Intervallo di 1 settimana:
$41.15
$45.63
Portata 52W:
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
43.82 | 3.49B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 Shares - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Q1 EPS Estimate for Akero Therapeutics Boosted by Analyst - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 50,000 Shares of Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $48,090.00 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Decreased by Y Intercept Hong Kong Ltd - MarketBeat
Trading (AKRO) With Integrated Risk Controls - Stock Traders Daily
Akero therapeutics chief scientific officer sells $556,590 in stock By Investing.com - Investing.com Australia
Akero therapeutics chief scientific officer sells $556,590 in stock - Investing.com
Short Interest in Akero Therapeutics, Inc. (NASDAQ:AKRO) Increases By 32.0% - MarketBeat
HC Wainwright Issues Optimistic Estimate for AKRO Earnings - Defense World
Akero Therapeutics (NASDAQ:AKRO) Given New $75.00 Price Target at HC Wainwright - MarketBeat
Akero Therapeutics senior VP sells $48,090 in stock By Investing.com - Investing.com South Africa
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - News & Insights
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Akero Therapeutics senior VP sells $48,090 in stock - Investing.com India
Akero Therapeutics Executives Sell Shares - TradingView
Akero therapeutics COO Jonathan Young sells $2.24 million in stock By Investing.com - Investing.com UK
Y Intercept Hong Kong Ltd Has $249,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Up 32.0% in February - Defense World
Akero Therapeutics (NASDAQ:AKRO) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - Markets Insider
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akero Therapeutics stock target raised to $75 by H.C. Wainwright - Investing.com India
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Lifted by Rhumbline Advisers - Defense World
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - MSN
Akero Therapeutics (AKRO) to Release Earnings on Friday - MarketBeat
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Akero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
3 Mid-Caps Worth Watching Closely in March - MarketBeat
Akero Therapeutics, Inc. SEC 10-K Report - TradingView
Akero Therapeutics Q4 Loss Unchanged -February 28, 2025 at 07:27 am EST - Marketscreener.com
Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Total Operating Expenses $78M - Marketscreener.com
Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Loss $-0.99 Per Share, vs. FactSet Est of $-1.14 - Marketscreener.com
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Can Akero's Breakthrough Cirrhosis Reversal Results Reshape MASH Treatment Landscape? - StockTitan
IMMINENT AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts? - MSN
Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Thursday - Defense World
Madrigal’s Rezdiffra Continues Its Solid Launch - Scrip
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant - MSN
10 Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 10,000 Shares of Stock - MarketBeat
Akero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025 - MSN
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):